Ranbaxy recalls drug in Canada; Pfizer U.K. facility demolished;

> Ranbaxy Pharmaceuticals Canada, a Ranbaxy subsidiary, has recalled one batch of RAN-gabapentin, a medication used to treat epilepsy, because of cross-contamination during the manufacturing process with Etodolac, a nonsteroidal anti-inflammatory drug. Report

> India will toughen up the rules that drugmakers there must follow about the authenticity of data used to support drugs manufactured there or imported for use there. Report

> Recipharm has made a $2 million equity investment in Synthonics, which allows Synthonics access to Recipharm's drug development and manufacturing expertise in exchange for royalties on some of its APIs. Release

> A former Pfizer ($PFE) distribution center in Hampshire, U.K., will be demolished to make way for a new development. Report

> American Health Packaging in Columbus, Ohio, is recalling 2,284 cartons of benzonatate capsules after receiving reports that they were wet. Report

Suggested Articles

Gilead expects to sell 1 million to 1.5 million treatment courses of remdesivir in 2020. That means about $3.5 billion in sales, one analsyt figures.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Warp Speed's largest outlay to date, the funding will cover development and manufacturing scale-up of a vaccine that uses proven Sanofi technology.